DRW Securities’s Agile Therapeutics AGRX Stock Holding History

DRW Securities’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-19	Closed	-$19K	–	105
2018 Q2	$19K	Buy	+19	New	+$66.7K	﹤0.01%	98

Other funds holding AGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DRW Securities's AGRX Position: Q3 2018 in Review

DRW Securities sold out of Agile Therapeutics (AGRX) in Q3 2018, closing a stake of 19 shares — an estimated $19K sold.

DRW Securities first reported a position in AGRX in Q2 2018 and held it in 1 quarter. The position peaked at $19K in Q2 2018. 29 funds tracked by Wall St. Rank hold AGRX as of Q3 2018.

DRW Securities reported no remaining Agile Therapeutics position as of Q3 2018 after selling out during the quarter.
DRW Securities sold 19 Agile Therapeutics shares in Q3 2018, an estimated $19K.
DRW Securities first reported a position in Agile Therapeutics in Q2 2018 and held it in 1 quarter.
DRW Securities's Agile Therapeutics position peaked at $19K in Q2 2018.
29 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2018.

Based on DRW Securities's 13F filing for Q3 2018, filed 14 Nov 2018.